Unither Pharmaceuticals Announces Acquisition of Nanjing Ruinian Best Pharmaceutical to Expand in China's Sterile Single-Dose Market

August 25, 2020 – Paris, France / Jiangsu, China: Unither Pharmaceuticals, the global leader in sterile single-dose formulations, has launched the acquisition of Nanjing Ruinian Best Pharmaceutical Co., Ltd., a Chinese pharmaceutical company.

Through the acquisition of Best, Unither will strengthen its development in China, the world’s second-largest pharmaceutical market, complementing its industrial footprint beyond Europe, the United States, and Brazil. Eric Goupil, CEO of Unither, explained, “We are delighted to welcome this new company into the Unither Group, which will enable us to carry out processing operations locally in China. This aligns with our strategy of manufacturing close to end markets.”

Through this acquisition, Unither Pharmaceuticals will provide services to domestic and multinational pharmaceutical companies developing ophthalmic and respiratory markets in China, by locally manufacturing sterile, preservative-free, single-dose formulations.

About Nanjing Unither Pharmaceuticals Co., Ltd.

Nanjing Unither Pharmaceuticals Co., Ltd. is a pharmaceutical enterprise located in Nanjing, Jiangsu Province, specializing in the production of solid and liquid dosage forms. With an annual turnover of €10 million and 130 employees, it is a key asset of Wuxi Jinyuan Industrial Investment Development Group Co., Ltd., the government-backed investment platform of Binhu District, Wuxi City.

About Unither Pharmaceuticals Group

Unither Pharmaceuticals was established in 1993 through the acquisition of a factory in Amiens, France, which had 17 employees. Today, as a global leader in pharmaceutical manufacturing, it produces sterile unit-dose formulations and strip-packaged formulations for originator and generic drug clients, including eye drops, nasal care solutions, and nebulized inhalation medications.

Unither Group operates six production sites and one innovation and R&D center in France, the United States, and Brazil, with a 2019 turnover of €319 million. The Group currently employs more than 1,500 people and continues to consolidate its global leadership in the manufacture of sterile formulations using blow-fill-seal (BFS) technology.

In March 2017, Unither Group completed its fourth round of financing and acquisition, with Ardian, Keensight Capital, and Parquest Capital acquiring shares from the original shareholders, Equistone Partners Europe, and the management team.

Responsible Editor: Liuli

Disclaimer: This article is reposted from Yaozhi.com. The copyright belongs to the original author. The content is shared for the purpose of disseminating information and does not represent the views of this platform. If there are any issues regarding the content, copyright, or other matters, please leave a message on our website, and we will remove the content promptly.